Drug intelligence / Profile preview

citicoline + Anapsos + piracetam

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of three substances with potential synergistic effects on cognitive function and neuroprotection. Citicoline (CDP-choline) is a precursor to acetylcholine and plays a role in phospholipid synthesis, supporting brain cell membrane integrity. Piracetam is a nootropic that enhances acetylcholine utilization, improves cerebral blood flow, and has neuroprotective properties. Anapsos, derived from the fern Polypodium leucotomos, has immunomodulatory effects. The combination may provide enhanced cognitive benefits through multiple complementary mechanisms.

Brand names: CEREBROLITE PM
Other names: CDP-choline + Anapsos + piracetam

Targets

AMPAR (AMPA receptor)CHT1 (High-affinity choline transporter 1)CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)

Beyond the preview

Go deeper on citicoline + Anapsos + piracetam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on citicoline + Anapsos + piracetam.

Explore the full profile